novo nordisk glp-1 weight loss Nordisk's weight-loss pill wins FDA approval Novo's Lars Rebien hints at

Connected health devices like smart scales allow the care team to track progress between visits all from the comfort of home

The effects remain an area of active research [2][19][20]

Off-Label Marketing Risk Manufacturers of GLP-1 medications may face regulatory scrutiny and legal risks if they promote their products for off-label use or disseminate inaccurate and misleading information

Semaglutide has demonstrated a wide range of benefits within the GLP-1 class beyond glycemic control and weight loss, particularly for people with cardiometabolic disease

Subarachnoid Hemorrhage (SAH): Confirmed via post-mortem examination and deemed incompatible with study objectives

However, oral LC supplementation increases the levels of trimethylamine- N -oxide (TMAO) [12], which, as a pro-atherogenic factor, has been indicated to increase the risk of cardiovascular disease (CVD) [13], chronic kidney disease (CKD) [14], and even cancer [15]